China NMPA approves clinical trial of Gannex’s ASC42 for liver disease
Category: #healthcare  By Akshay Kedari  Date: 2021-09-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

China NMPA approves clinical trial of Gannex’s ASC42 for liver disease

Biotech company Gannex Pharma Co. Ltd. recently announced that the China National Medical Products Administration (NMPA) accepted its clinical trial application of ASC42 for treating patients with primary biliary cholangitis (PBC), a chronic form of liver disease resulting from progressive destruction of the bile ducts in the liver.

For the unversed, Gannex is an Ascletis wholly-owned company focused on the development and commercialization of novel non-alcoholic steatohepatitis (NASH) medications. The firm has three clinical-stage therapeutic candidates targeting FASN, THR-beta, and FXR, as well as three fixed-dose combos.

ASC42 is a unique non-steroidal, selective, and strong FXR agonist developed in-house with best-in-class potential. Gannex revealed positive topline results of safety and pharmacodynamic indicators from the ASC42 Phase I study in the United States on June 16, 2021.

It is to be noted that no pruritus or itch was found during 14 days of therapy with the once-daily human therapeutic dose of 15 mg. FGF19, the FXR target engagement biomarker, surged by 1632% on the 14th day of treatment with the 15 mg dose.

PBC is a chronic autoimmune cholestatic illness that often proceeds towards liver fibrosis and cirrhosis, necessitating liver transplantation or resulting in death, as stated by Recommendations for diagnosis and treatment of primary biliary cholangitis in China (2021).

According to a 2010 epidemiology study, the prevalence of PBC in China was 49.2 instances per 100,000 individuals, with 155.8 cases per 100,000 in women over 40, implying a total of 656,000 PBC patients in China, including 440,000 females over 40.

The only drug approved in China that can delay disease progression is ursodeoxycholic acid (UDCA). However, over 40% of PBC patients have an insufficient response to UDCA or cannot tolerate it. Thus, there is an enormous unmet medical need for developing novel medications for PBC patients, such as ASC42.

Source Credit- https://www.prnewswire.com/news-releases/gannex-announces-clinical-trial-application-of-asc42-an-fxr-agonist-for-treatment-of-primary-biliary-cholangitis-accepted-by-china-nmpa-301369589.html

 

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

AstraZeneca shares soar as Enhertu found to reduce breast cancer risks
AstraZeneca shares soar as Enhertu found to reduce breast cancer risks
By Akshay Kedari

Shares of AstraZeneca plc have witnessed a substantial hike after it revealed positive results from ...

Investors urge governments to tighten climate accounting protocols
Investors urge governments to tighten climate accounting protocols
By Akshay Kedari

Investors controlling over USD 2.5 trillion have reportedly urged governments to require auditors an...

Indonesia in talks with WHO to become global vaccine manufacturing hub
Indonesia in talks with WHO to become global vaccine manufacturing hub
By Akshay Kedari

Indonesia is in discussion with the World Health Organization (WHO) together with six pharma compani...